Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Telomir Pharmaceuticals, Inc. ( (TELO) ) has shared an announcement.
Telomir Pharmaceuticals announced new in vitro results for Telomir-1, showcasing its potential as a first-in-class epigenetic therapy. The findings reveal Telomir-1’s dual action in targeting DNA methylation switches and interfering with the Wnt signaling pathway, which could impact cancer growth and treatment resistance. The drug’s selectivity and ability to reset DNA methylation patterns without affecting telomere biology suggest a promising safety profile and therapeutic potential in treating cancer and age-related diseases.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing therapies that target the root mechanisms of cancer, aging, and age-related diseases.
Average Trading Volume: 3,181,033
Technical Sentiment Signal: Sell
Current Market Cap: $48.1M
For detailed information about TELO stock, go to TipRanks’ Stock Analysis page.